Novartis AG (NVS)
92.57
-0.51
(-0.55%)
USD |
NYSE |
Apr 18, 16:00
93.06
+0.49
(+0.53%)
Pre-Market: 08:32
Novartis Cash and Short Term Investments (Quarterly): 13.96B for Dec. 31, 2023
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 13.96B |
September 30, 2023 | 12.70B |
June 30, 2023 | 11.17B |
March 31, 2023 | 12.26B |
December 31, 2022 | 18.62B |
September 30, 2022 | 19.10B |
June 30, 2022 | 19.76B |
March 31, 2022 | 18.81B |
December 31, 2021 | 28.11B |
September 30, 2021 | 8.162B |
June 30, 2021 | 5.356B |
March 31, 2021 | 4.077B |
December 31, 2020 | 11.29B |
September 30, 2020 | 10.87B |
June 30, 2020 | 6.293B |
March 31, 2020 | 4.973B |
December 31, 2019 | 11.23B |
September 30, 2019 | 8.717B |
June 30, 2019 | 10.34B |
March 31, 2019 | 7.112B |
December 31, 2018 | 15.96B |
September 30, 2018 | 14.71B |
June 30, 2018 | 13.15B |
March 31, 2018 | 6.422B |
December 31, 2017 | 9.485B |
Date | Value |
---|---|
September 30, 2017 | 9.421B |
June 30, 2017 | 8.437B |
March 31, 2017 | 8.237B |
December 31, 2016 | 7.777B |
September 30, 2016 | 7.785B |
June 30, 2016 | 5.74B |
March 31, 2016 | 5.086B |
December 31, 2015 | 5.447B |
September 30, 2015 | 6.064B |
June 30, 2015 | 5.875B |
March 31, 2015 | 7.363B |
December 31, 2014 | 13.86B |
September 30, 2014 | 10.43B |
June 30, 2014 | 7.335B |
March 31, 2014 | 7.721B |
December 31, 2013 | 9.222B |
September 30, 2013 | 7.339B |
June 30, 2013 | 5.25B |
March 31, 2013 | 6.035B |
December 31, 2012 | 8.119B |
September 30, 2012 | |
June 30, 2012 | |
March 31, 2012 | |
December 31, 2011 | 5.075B |
September 30, 2011 |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
4.077B
Minimum
Mar 2021
28.11B
Maximum
Dec 2021
12.41B
Average
11.23B
Median
Dec 2019
Cash and Short Term Investments (Quarterly) Benchmarks
Sandoz Group AG | -- |
Amgen Inc | 10.94B |
AstraZeneca PLC | 5.86B |
Incyte Corp | 3.656B |
MorphoSys AG | 754.72M |